(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit (macitentan) trajectory and new patient referrals sustained Continued outstanding US launch momentum for Uptravi (selexipag), Q2 launches in Germany, Canada (private market) and France (cohort ATU) Initiation of Phase III study to evaluate the efficacy and safety of long-term use of macitentan (Opsumit) for the treatment of children with PAH Initiation of Phase II program with new dual orexin receptor antagonist for the treatment of insomnia FINANCIAL HIGHLIGHTS Sales of CHF 1,179 million (+13% at...
↧